Eloxx Pharmaceuticals announces FDA clearance of investigational new drug application for Exaluren in nonsense-mutation ADPKD
ELOX•Eloxx Pharmaceuticals said the FDA cleared its investigational new drug application for Exaluren in nonsense-mutation ADPKD. The company plans to randomize 60 patients, begin dosing in the third quarter of 2027 and report topline data in the first half of 2029.
1. Trial plans
Eloxx Pharmaceuticals announced FDA clearance of its investigational new drug application for Exaluren in nonsense-mutation ADPKD. The company plans to randomize 60 patients, begin dosing in the third quarter of 2027 and report topline data in the first half of 2029.
